Patents by Inventor Nai-Kong Cheung

Nai-Kong Cheung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200291112
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of A33 protein. The antibodies of the present technology are useful in methods for detecting and treating an A33-positive cancer in a subject in need thereof.
    Type: Application
    Filed: September 21, 2018
    Publication date: September 17, 2020
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Zhihao WU, Hong XU, Nai-Kong CHEUNG
  • Publication number: 20200140543
    Abstract: Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.
    Type: Application
    Filed: February 9, 2016
    Publication date: May 7, 2020
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Sarah CHEAL, Hong XU, Steven LARSON, Nai-Kong CHEUNG, Karl Dane WITTRUP, Alice TZENG
  • Patent number: 10287365
    Abstract: In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: May 14, 2019
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Nai-Kong Cheung, Mahiuddin Ahmed, Hong Xu
  • Publication number: 20180127503
    Abstract: The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.
    Type: Application
    Filed: March 10, 2016
    Publication date: May 10, 2018
    Inventors: Cheng LIU, Su YAN, Pei WANG, Nai-Kong CHEUNG, Hongfen GUO, Ming CHENG
  • Publication number: 20170253660
    Abstract: In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 7, 2017
    Inventors: Nai-Kong Cheung, Mahiuddin Ahmed, Hong Xu
  • Patent number: 9688772
    Abstract: In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: June 27, 2017
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Nai-Kong Cheung, Mahiuddin Ahmed, Hong Xu
  • Patent number: 9453075
    Abstract: Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab?)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: September 27, 2016
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Nai-Kong Cheung, Dimiter Tassev, Jian Hu
  • Patent number: 9416422
    Abstract: The present invention features methods and compositions for identifying markers of minimum residual disease (MRD), as well as markers of metastatic cells. The present invention further provides methods for detecting MRD and metastatic cell in a subject.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: August 16, 2016
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventor: Nai-Kong Cheung
  • Publication number: 20160176981
    Abstract: In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.
    Type: Application
    Filed: November 19, 2015
    Publication date: June 23, 2016
    Inventors: Nai-Kong Cheung, Mahiuddin Ahmed, Hong Xu
  • Patent number: 9315585
    Abstract: In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: April 19, 2016
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Nai-Kong Cheung, Mahiuddin Ahmed, Hong Xu
  • Patent number: 9040669
    Abstract: Antigen binding proteins with T cell receptor-like paratopes, that is, with an antigen binding region specific for an human leukocyte antigen-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab?)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: May 26, 2015
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Nai-Kong Cheung, Dimiter Tassev, Jian Hu
  • Publication number: 20140296492
    Abstract: Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab?)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.
    Type: Application
    Filed: June 9, 2014
    Publication date: October 2, 2014
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Nai-Kong CHEUNG, Dimiter Tassev, Jian Hu
  • Publication number: 20140024809
    Abstract: Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab?)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.
    Type: Application
    Filed: February 13, 2012
    Publication date: January 23, 2014
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Nai-Kong Cheung, Dimiter Tassev, Jian Hu
  • Publication number: 20130216528
    Abstract: In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.
    Type: Application
    Filed: June 20, 2011
    Publication date: August 22, 2013
    Inventors: Nai-Kong Cheung, Mahiuddin Ahmed
  • Patent number: 7666424
    Abstract: This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collection of cells with an anti-idiotype directed to an antibody specific for the target antigen and detecting interaction, if any, of the anti-idiotype with the cells, wherein the occurrence of an interaction identifies the cell as one which expresses the target scFv. This invention also provides a method for making a single chain antibody (scFv) directed against an antigen, wherein the selection of clones is made based upon interaction of those clones with an appropriate anti-idiotype, and heretofore inaccessible scFv so made. This invention provides the above methods or any combination thereof. Finally, this invention provides various uses of these methods.
    Type: Grant
    Filed: October 17, 2002
    Date of Patent: February 23, 2010
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Nai-Kong Cheung, Hong-Fen Guo
  • Publication number: 20090023142
    Abstract: The present invention features methods and compositions for identifying markers of minimum residual disease (MRD), as well as markers of metastatic cells. The present invention further provides methods for detecting MRD and metastatic cell in a subject.
    Type: Application
    Filed: February 17, 2006
    Publication date: January 22, 2009
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventor: Nai-Kong Cheung
  • Publication number: 20060188506
    Abstract: This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance. which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition.
    Type: Application
    Filed: July 16, 2004
    Publication date: August 24, 2006
    Inventor: Nai-Kong Cheung
  • Publication number: 20060160766
    Abstract: A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal, and at least one antibody for the cancer. A method of treating cancer in a mammal is also disclosed. The method comprises administering a suitable orally administered glucan and at least one antibody for the treatment of cancer to the mammal. In addition a composition for delivery of peptide, protein, RNA, DNA or plasmid comprising effective amount of a beta-glucan is disclosed.
    Type: Application
    Filed: January 17, 2006
    Publication date: July 20, 2006
    Inventor: Nai-Kong Cheung
  • Publication number: 20060063179
    Abstract: Compositions and methods are provided for the identification of partner genes with MLL. Also provided is a new partner gene of MLL termed MIFL.
    Type: Application
    Filed: August 8, 2005
    Publication date: March 23, 2006
    Inventors: Carolyn Felix, Blaine Robinson, Nai-Kong Cheung
  • Publication number: 20060051359
    Abstract: Immunotoxins are disclosed that include a toxin, a variable region of a heavy chain of a monoclonal antibody that binds the antigen specifically bound by monoclonal antibody 8H9, and a variable region of a light chain of the monoclonal antibody that binds the antigen specifically bound by monoclonal antibody 8H9 and effector molecule. These immunotoxins include scFv and dsFv of monoclonal antibody 8H9. The immunotoxins are of use for the treatment of tumors.
    Type: Application
    Filed: December 1, 2003
    Publication date: March 9, 2006
    Inventors: Ira Pastan, Masanori Onda, Nai-Kong Cheung